Analysis: U.S. midterms dampen Big Pharma hopes for drug price policy change
WASHINGTON, Nov 18 (Reuters) – The divided Congress after the November midterm elections undermines pharmaceutical companies who want to weaken a new law that allows the government to negotiate drug prices, Republican strategists, policy experts and pharmaceutical executives
Read More